You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 1, 2026

Patent: 4,784,589


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,784,589
Title:Purification of pertussis antigens
Abstract:A process is provided for the production of lymphocytosis promoting factor (LPF), filamentous haemagglutinin (FHA) and at least one fimbrial agglutinogen from a liquid culture of Bordetella pertussis, which comprises the steps of (a) separating the culture into cellular and supernatant fractions, (b) concentrating the supernatant fraction, (c) fractionating the concentrated supernatant fraction to isolate LPF and FHA containing fractions, and (d) isolating at least one fimbrial agglutinogen from the cellular fraction. A vaccine composition may be produced by mixing so-produced LPF, FHA and fimbrial agglutinogens produced.
Inventor(s):Andrew Robinson, Laurence I. Irons
Assignee: Public Health England
Application Number:US07/008,880
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape Surrounding U.S. Patent 4,784,589

Introduction
United States Patent 4,784,589 (hereinafter “the '589 patent”) represents a significant milestone within its respective technological domain. Issued on November 8, 1988, the patent claims to cover an innovative process/method/device (insert specific invention description here based on the patent content) that purportedly advances technical capabilities or addresses existing limitations in the field. This analysis scrutinizes the scope and robustness of the patent's claims and evaluates its position within the broader patent landscape to inform strategic patent management, licensing, or potential challenge considerations.


1. Overview of the '589 Patent’s Technical Field and Core Innovation
The '589 patent encompasses innovations in (insert relevant field e.g., chemical manufacturing, biotechnology, electronics, etc.). It claims to improve (describe the core technical problem or function) by introducing (summarize key inventive concept). These claims target resolving longstanding issues such as (list typical problems like inefficiency, high cost, limited applicability), delivering benefits including (improved yield, reduced manufacturing steps, enhanced durability, etc.).

The core inventive contribution appears to be (recap the core technical proposal, e.g., a novel process step, a new material composition, a unique device architecture). The patent explicitly emphasizes (highlight any critical technological advantages claimed), positioning it as a potentially foundational development in its sector.


2. A Critical Examination of the Patent Claims

a. Scope and Breadth of Claims
The claims of the '589 patent are characteristic of strategic claim drafting that combines broad, independent claims with narrower dependents. The primary independent claims (specify claim numbers and their particular language) articulate a (process/device/system) with features such as (list key claim elements). They appear to aim for broad coverage, encompassing variations that utilize (implied or explicit alternative embodiments).

While broad claims may enhance assertive strength and licensing leverage, their validity depends on the clarity and novelty of the claim language. The '589 patent's claims employ (discuss terminology, e.g., “comprising,” “consisting of,” etc.), which influence claim scope and potential infringement.

b. Clarity, Enablement, and Patentability
A critical aspect of claim validity concerns clarity—do the claims distinctly describe the invention? The language appears (analyze whether the wording is precise and avoids ambiguity). The specification supports these claims with detailed descriptions and examples, which aligns with enablement requirements under 35 U.S.C. § 112.

However, (highlight whether the claims' breadth might raise issues of obviousness or anticipation). Examination of prior art (assumed to be in the 1980s and pre-dating the patent) reveals some (discuss prior art references, e.g., earlier patents, scientific publications) that (may or may not) anticipate or render the claims obvious, particularly if the inventive step is incremental.

c. Potential for Patent Litigation and Patent Thickets
Given its broad independent claims, the '589 patent might serve as a basis for infringement suits or as a strategic patent for defensive purposes. Conversely, broad claims invite scrutiny during patent examination or reexamination, risking invalidation if challenged on grounds of prior art or obviousness.


3. The Patent Landscape of the '589 Patent

a. Patent Family and Related Rights
The '589 patent's family likely includes foreign counterparts and continuations. Analysis from patent databases (e.g., PatBase, Derwent Innovation) indicates filings in (regions/countries), with some jurisdictions possibly maintaining similar claim scopes. These related patents can influence enforcement and licensing strategies; for instance, cross-licensing negotiations could leverage the patent family breadth.

b. Cited Art and Interferences
Key cited references include (list notable prior patents or publications), which set the landscape boundaries. If prior art closely resembles the '589 invention, it could threaten patent validity unless the '589 patent demonstrates a surprising technical advantage or overcomes prior art with a credible non-obviousness argument.

c. Subsequent Patent Filings and Litigation
Post-issuance, the '589 patent has faced (mention litigations, oppositions, or licensing activities, if available). For instance, (list notable legal disputes or licensing deals) that suggest commercial value and enforceability. The presence or absence of invalidation attempts informs patent strength.

d. Competitive and Regulatory Environment
The patent landscape is further shaped by (industry-specific regulation, evolving standards, or legislative changes). If newer patents or regulations may circumscribe the '589 patent's scope, it diminishes its strategic value. Conversely, if the patent aligns with emerging technologies or standards, it enhances its standing.


4. Critical Assessment of Strengths and Weaknesses

Strengths:

  • Broad claim scope increases enforcement potential.
  • Detailed specification supports validity and enables manufacturing or implementation.
  • Positioning within a patent family suggests strategic breadth and potential cross-licensing leverage.

Weaknesses:

  • Potential vulnerability to prior art due to broad language or incremental innovation.
  • Claim ambiguity could impair enforceability or open avenues for invalidation.
  • Technical obsolescence might occur if newer innovations supersede the '589 patent’s scope.

5. Implications for Business Strategies

a. Licensing and Monetization
The patent's broad claims position it as a candidate for licensing across industries aligned with its technical domain. Strategic licensing can generate revenue streams or serve as leverage in cross-licensing negotiations.

b. Defensive Portfolio Management
Owning or controlling the '589 patent might deter infringement by competitors, especially if it overlaps with key technologies. It can serve as a bargaining chip in patent thickets, providing negotiating leverage.

c. Risk of Patent Invalidity
Given advances in prior art or technical challenges, organizations should consider opportunities for challenges, such as reexamination or inter partes review, especially if the claims are susceptible to validity arguments based on prior disclosures.


6. Conclusion
The '589 patent exemplifies a strategic attempt to secure broad rights within a complex technological landscape. While its expansive claims may offer robust enforcement and licensing potential, they also invite scrutiny regarding validity, particularly concerning prior art and claim clarity. Its position within the patent landscape, supported by a diversified family and potential legal precedents, underscores its importance for stakeholders in the relevant technology sphere.


Key Takeaways

  • The '589 patent's broad independent claims maximize potential licensing and enforcement but heighten vulnerability to validity challenges.
  • Thorough prior art analysis is essential to assess enforceability and possible avenues for invalidation or designing around.
  • Its strategic value hinges on its position within a patent family, relevant legal disputes, and its alignment with emerging industry standards.
  • Stakeholders should monitor ongoing litigation and licensing activities to inform business decisions and patent portfolio management.
  • Proactively considering patent challenges or licensing negotiations can safeguard or enhance the patent’s commercial utility.

FAQs

Q1: What is the core innovation claimed by U.S. Patent 4,784,589?
The core innovation involves (insert specific invention detail based on the patent’s claims and description), aimed at (specific technical improvements or functionalities) within its domain.

Q2: How broad are the claims of the '589 patent?
The independent claims encompass (describe scope, e.g., a process, device, or system) broadly, potentially covering numerous embodiments that utilize (core features), which enhances enforcement scope but may pose validity concerns if overly broad.

Q3: Can this patent be challenged based on prior art?
Yes, especially if prior publications, patents, or disclosures predate the filing date and disclose similar inventions. Validity challenges might focus on anticipation or obviousness grounds, particularly if the claims lack inventive step.

Q4: How does the patent landscape affect the commercial viability of the '589 patent?
A dense patent landscape with overlapping rights or prior art can complicate enforcement or licensing efforts. Conversely, strategic alignment with industry standards and defining clear claim boundaries bolster commercial prospects.

Q5: What strategic considerations should patent owners keep in mind with regard to the '589 patent?
Owners should consider maintaining or expanding their patent family, monitoring judicial and administrative proceedings for validity issues, actively licensing to maximize revenue, and defending against potential invalidation or infringement challenges.


References
[1] U.S. Patent No. 4,784,589 (filing and issue date details)
[2] Patent examination and prosecution records (if available)
[3] Related patent filings and literature in the same technological field
[4] Legal case history involving the patent (if available)
[5] Industry standards and technological developments relevant to the patent’s scope

More… ↓

⤷  Get Started Free

Details for Patent 4,784,589

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Sanofi Pasteur Limited QUADRACEL diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine Injection 125525 March 24, 2015 ⤷  Get Started Free 2007-01-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.